At the last check on Thursday, Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) stock was up $8.47, moving up 3.11 percent to $280.78. The average number of shares traded per day over the past five days has been 1,638,783 shares. 5 times new highs have been achieved over the past 5 days, with a $27.08 gain in that time frame. In the last twenty days, the average volume was 1,564,031, while in the previous 50 days, it was 1,674,302.
Since last month, VRTX stock rose 5.31%. Shares of the company fell to $243.17 on 06/14/22, the lowest level in the past month. A 52-week high of $292.75 was reached on 04/14/22 after having rallying from a 52-week low of $176.36. Since the beginning of this year, VRTX’s stock price has risen by 24.00% or $60.99, and marked a new high 24 times. However, the stock has declined by -4.09% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Vertex Pharmaceuticals Incorporated (VRTX) last reported insider trading activity 38 days ago on May 16. Sanna Bastiano, the EVP, Cell & Genetic Therapies of the company, disposed of 45 shares for $252.83 on May 16. It resulted in a $11,377 divestment by the insider. Arbuckle Stuart A sold 133 shares at an average price of $251.19 on May 16. The insider now owns 64,760 shares following the transaction. On May 16, SVP, General Counsel Liu Joy sold 133 shares at $252.88 apiece. The transaction was valued at $33,633.
Right now, Vertex Pharmaceuticals Incorporated (VRTX) has a P/E ratio of about 28.70. The stock’s beta is 0.56. Besides these, the trailing price-to-sales (P/S) ratio of 8.36, the price-to-book (PB) ratio of 6.37, and the price-to-cash flow ratio of 27.11 may also be considered.
In the three months ended March 30, Vertex Pharmaceuticals Incorporated’s quick ratio stood at 4.60, while its current ratio was 4.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.05, and the total debt-to-equity ratio was 0.05. On the profitability front, the trailing twelve-month gross margin is 88.00% percent. In the year ended March 30, operating margins totaled 36.90%. Based on annual data, VRTX earned $6.67 billion in gross profit and brought in $7.57 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 22.50%. Return on equity (ROE) for the past 12 months was 24.70%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. VRTX’s revenue rose 17.79% to $2.07 billion during the quarter, while net income inched up to $2.1 billion. While analysts expected Vertex Pharmaceuticals Incorporated to report $3.49 quarterly earnings, the actual figure was $3.52 per share, beating the consensus estimate by 0.90%. During the quarter, the company generated $1.08 billion in EBITDA. The liabilities of Vertex Pharmaceuticals Incorporated were 3.35 billion at the end of its most recent quarter ended March 30, and its total debt was $967.4 million. The value of shareholders’ equity is $255.76 million.
This quick technical analysis looks at Vertex Pharmaceuticals Incorporated’s (VRTX) price momentum. With a historical volatility rate of 39.16%, the RSI 9-day stood at 68.11% on 22 June.
With respect to its five-day moving average, the current Vertex Pharmaceuticals Incorporated price is up by +10.68% percent or $27.08. At present, VRTX shares trade +4.51% above its 20-day simple moving average and +15.46% percent above its 100-day simple moving average. However, the stock is currently trading approximately -0.18% below its SMA50 and +45.99% above its SMA200.
Stochastic coefficient K was 84.20% and Stochastic coefficient D was 72.22%, while ATR was 9.07. Given the Stochastic reading of 96.48% for the 14-day period, the RSI (14) reading has been calculated as 62.17%. As of today, the MACD Oscillator reading stands at 14.36, while the 14-day reading stands at 11.25.
Maxim Group upgraded its rating on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to a Buy in a note to investors on June 01, 2022. The analysts firm previously had a Hold rating on the stock.Vertex Pharmaceuticals Incorporated (VRTX) has been rated Overweight by analysts. According to 0 brokerage firms, VRTX is a sell, and 9 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate Vertex Pharmaceuticals Incorporated stock as buy, with 15 recommending it as overweight.
With a median target price of $289.50, the current consensus forecast for the stock is $240.00 – $368.00. Based on these forecasts, analysts predict Vertex Pharmaceuticals Incorporated (VRTX) will achieve an average price target of $294.73.